Optimize Meds for Peripheral Artery Disease
Debate will brew about how to manage stable peripheral artery disease (PAD)...now that Xarelto (rivaroxaban) is approved for this use.
Think of managing PAD as similar to coronary artery disease.
Plaque buildup puts PAD patients at high risk of complications, such as CV events or limb amputation. And they may develop symptoms...such as claudication or pain that reduces walking distance and quality of life.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote